Tirzepatide vs Retatrutide
Verdict: Retatrutide posted the most dramatic weight-loss numbers ever seen in a trial — around 24% at 48 weeks in phase 2 — by adding glucagon receptor activity (energy expenditure) to tirzepatide's GIP/GLP-1 combination. But tirzepatide is an approved medicine with years of real-world safety data; retatrutide is still in trials, so everything circulating outside them is unverified research material. On evidence-to-risk ratio, tirzepatide remains the sane default; retatrutide is the frontier.
Side by side
| Tirzepatide | Retatrutide | |
|---|---|---|
| Typical dose | 2.5 mg–15 mg | 1 mg–12 mg |
| Frequency | 1x weekly, titrated up | 1x weekly, titrated up |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 5 mg, 10 mg, 15 mg, 30 mg | 5 mg, 10 mg |
| Typical mix | 10 mg + 2 ml water | 10 mg + 2 ml water |
| Units for typical dose | 50 units (2.5 mg) | 40 units (2 mg) |
The third receptor
Glucagon agonism is retatrutide's differentiator: instead of only reducing intake (satiety, slower gastric emptying), it raises energy output — the body burns more at rest. That's why its trial curves kept dropping when dual-agonist curves began to plateau. The same mechanism demands respect: glucagon activity touches heart rate and hepatic glucose output, which is exactly what phase 3 is still characterizing.
Dosing reality
Tirzepatide has an approved, printed titration schedule. Retatrutide doses in circulation (1–12 mg weekly) are extrapolated from trial arms, not from any approved label — there is no official answer to 'what's the right dose,' only what phase 2 cohorts received. Community protocols start at 0.5–1 mg weekly precisely because no guidance exists.
Supply-chain risk is part of the comparison
An approved drug comes from a pharmacy with QC; a pre-approval compound comes from research vendors with wildly variable purity. Whatever your position on gray-market GLP-1s, the practical rule stands: third-party testing certificates and conservative reconstitution math matter far more for retatrutide than for anything with a label.
Can you stack them?
Not stacked together — same pathway family. Retatrutide effectively *is* the stack, folding three incretin-axis mechanisms into one molecule.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.